We are only at the beginning of the genomics revolution.
Murrieta Genomics, LLC (MG) is a California Limited Liability Company specifically formed to provide specialized Next Generation Sequencing (NGS) services, training, education, business incubation and laboratory design and build services.
Genome sequencing is figuring out the order of DNA nucleotides, or bases, in a genome—the order of As, Cs, Gs, and Ts that make up an organism’s DNA. The human genome is made up of over 3 billion of these genetic letters.
Scientists still have to translate those strings of letters into an understanding of how the genome works: what the various genes that make up the genome do, how different genes are related, and how the various parts of the genome are coordinated. That is, they have to figure out what those letters of the genome sequence mean.
NGS is a disruptive genomics technology that allows scientists to sequence and assemble billions of short DNA reads. This technology is used for applications including human whole genome sequencing (WGS), whole exome sequencing, targeted sequencing using panels of a few to thousands of genes, and expression profiling (a.k.a. RNA-Seq).
Demand has never been greater for revolutionary technologies that deliver fast, inexpensive and accurate genome information. This challenge has catalyzed the development of NGS technologies. The inexpensive production of large volumes of sequence data is the primary advantage over conventional methods of data generation.
As with any new technology, challenges remain. In the case of NGS, these include the requirement for expertise in both the laboratory and in the analysis of huge datasets and the current need for high investment in laboratory and data analysis hardware.
As the technology is ever evolving towards lower cost, user-friendliness, and accessibility for smaller research and diagnostic labs, efforts are needed to make the data analysis more accessible to nonexpert users. This includes proper modeling of the sources of error introduction, solutions for public data storage, development of user- friendly but high standard analysis pipelines for routine applications, etc.
There are many local researchers who need access to this technology in order to take their concepts from laboratory to market. MG is uniquely positioned to provide not only the technology and domain knowledge to accelerate their progress; members of MG have strong experience in technology transfer, entrepreneurship and growing early stage companies.
MG can provide cost effective sequencing and interpretation while training customers on the sequencing process to transition to their own labs as they grow volume. MG has strong existing relationships with multiple equipment vendors to provide full turnkey lab build out and integration when the respective business grow to the point of bringing sequencing in house.
In partnership with MG, genomic scientists and entrepreneurs will be able to test and prove their concepts, whether they relate to medicine, agriculture, forensics, veterinary, consumer or other markets. The access to in-house sequencing will help to define and grow their sequencing business with greatly reduced risk.
The MG team has over 20 years of experience building sequencing labs providing valuable insight identifying specific needs and savings tailored to each client.